300 likes | 475 Views
Breast Plenary Abstracts<br />How Do These Studies Impact Clinical Practice Today and in the Years Ahead?<br />. Presented By Eric Winer at 2014 ASCO Annual Meeting.
E N D
Breast Plenary Abstracts<br />How Do These Studies Impact Clinical Practice Today and in the Years Ahead?<br /> Presented By Eric Winer at 2014 ASCO Annual Meeting
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive <br />early breast cancer (EBC) Presented By Eric Winer at 2014 ASCO Annual Meeting
N9831/B-31 Disease-Free Survival Presented By Eric Winer at 2014 ASCO Annual Meeting
Pathologic Response in Neo-ALTTO Presented By Eric Winer at 2014 ASCO Annual Meeting
CALGB 40601 (TH vs TL vs THL) Presented By Eric Winer at 2014 ASCO Annual Meeting
Adjuvant Lapatinib (ALTTO) Schema Presented By Eric Winer at 2014 ASCO Annual Meeting
Disease Free Survival (DFS) Analysis Presented By Eric Winer at 2014 ASCO Annual Meeting
Disease Free Survival By Hormone Receptor Status Presented By Eric Winer at 2014 ASCO Annual Meeting
Slide 9 Presented By Eric Winer at 2014 ASCO Annual Meeting
Overall Survival (OS) Analysis Presented By Eric Winer at 2014 ASCO Annual Meeting
Main Differences In AEs By Treatment Arm Presented By Eric Winer at 2014 ASCO Annual Meeting
Thoughts About ALTTO Presented By Eric Winer at 2014 ASCO Annual Meeting
Further Implications for Research and Practice Presented By Eric Winer at 2014 ASCO Annual Meeting
Why Improvement in Pathologic Complete Response May Not Lead to Change in DFS Presented By Eric Winer at 2014 ASCO Annual Meeting
Randomized Comparison of Adjuvant Aromatase Inhibitor <br />Exemestane plus Ovarian Function Suppression<br /> vs Tamoxifen plus Ovarian Function Suppression<br />in Premenopausal Women <br />with Hormone Receptor Positive Early Breast Cancer: <br />Joint Analysis of IBCSG TEXT and SOFT Presented By Eric Winer at 2014 ASCO Annual Meeting
Study Schemas (Total N=4690) Presented By Eric Winer at 2014 ASCO Annual Meeting
Improved DFS with Exemestane + OFS vs Tamoxifen + OFS Presented By Eric Winer at 2014 ASCO Annual Meeting
Sites of First Failure Presented By Eric Winer at 2014 ASCO Annual Meeting
Overall Survival at 5 Years Presented By Eric Winer at 2014 ASCO Annual Meeting
Women Who Did Not Receive Chemotherapy Presented By Eric Winer at 2014 ASCO Annual Meeting
Selected Adverse Events Presented By Eric Winer at 2014 ASCO Annual Meeting
Adverse Events and QOL Presented By Eric Winer at 2014 ASCO Annual Meeting
Slide 23 Presented By Eric Winer at 2014 ASCO Annual Meeting
Does Ovarian Suppression Add To Tamoxifen In Premenopasual Women?<br />Findings FromThe LHRH Meta-Analysis<br /> Presented By Eric Winer at 2014 ASCO Annual Meeting
Slide 25 Presented By Eric Winer at 2014 ASCO Annual Meeting
Primary End Point: Disease-Free Survival<br />No Significant Difference Between TAM and ANA Presented By Eric Winer at 2014 ASCO Annual Meeting
Is OS + AI The New Standard of Care? Presented By Eric Winer at 2014 ASCO Annual Meeting
What To Consider When You Go Home (1) Presented By Eric Winer at 2014 ASCO Annual Meeting
What To Consider When You Go Home (2) Presented By Eric Winer at 2014 ASCO Annual Meeting
Thank you Presented By Eric Winer at 2014 ASCO Annual Meeting